Roundtable Discussion: Device-Based CNS Delivery Strategies for Oligonucleotides
- Evaluate whether implantable and intrathecal delivery offer clear advantages over systemic approaches for CNS targeting
- Identify when device-based delivery outperforms systemic or ligand-mediated strategies
- Debate whether implantation limits use to rare diseases and how innovation could broaden applicability
- Examine key factors impacting distribution and reliability, including reservoir stability, catheter design, CSF flow, and dosing parameters
- Assess trade-offs between device-enabled delivery of simpler oligos and more complex chemical or conjugation strategies